Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (411-420 of 442) with videos related to

Pageof 45
Sort By:
Contemporary Clinical Trials Communications|July 25, 2017
Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD studyLiubov Robman, Robyn Guymer, Robyn Woods, et al.
Scientific Reports|March 22, 2022
Climate vulnerability assessment of key fishery resources in the Northern Humboldt Current SystemJorge E Ramos, Jorge Tam, Víctor Aramayo, et al.
Plos One|January 23, 2023
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virusAminata Sy, Leanne McCabe, Emma Hudson, et al.
HIV Medicine|March 4, 2014
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013Ed Wilkins, Mark Nelson, Kosh Agarwal, et al.
Plos One|July 8, 2022
Assessing the vulnerability of marine life to climate change in the Pacific Islands regionJonatha Giddens, Donald R Kobayashi, Gabriella N M Mukai, et al.
The Lancet. HIV|October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialJürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.
AIDS (London, England)|December 17, 2013
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppressionJemma L O'Connor, Colette J Smith, Fiona C Lampe, et al.
Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.
Journal of the American Society of Hypertension : JASH|July 28, 2018
Misclassification of blood pressure of Vietnamese adults when only a single measurement is usedNga T T Tran, Christopher L Blizzard, Khue N Luong, et al.
The New England Journal of Medicine|October 4, 2008
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, et al.
Pageof 45

Showing results (411-420 of 442) with videos related to

Sort By:
Pageof 45
Contemporary Clinical Trials Communications|July 25, 2017
Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD studyLiubov Robman, Robyn Guymer, Robyn Woods, et al.
Scientific Reports|March 22, 2022
Climate vulnerability assessment of key fishery resources in the Northern Humboldt Current SystemJorge E Ramos, Jorge Tam, Víctor Aramayo, et al.
Plos One|January 23, 2023
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virusAminata Sy, Leanne McCabe, Emma Hudson, et al.
HIV Medicine|March 4, 2014
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013Ed Wilkins, Mark Nelson, Kosh Agarwal, et al.
Plos One|July 8, 2022
Assessing the vulnerability of marine life to climate change in the Pacific Islands regionJonatha Giddens, Donald R Kobayashi, Gabriella N M Mukai, et al.
The Lancet. HIV|October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialJürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.
AIDS (London, England)|December 17, 2013
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppressionJemma L O'Connor, Colette J Smith, Fiona C Lampe, et al.
Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.
Journal of the American Society of Hypertension : JASH|July 28, 2018
Misclassification of blood pressure of Vietnamese adults when only a single measurement is usedNga T T Tran, Christopher L Blizzard, Khue N Luong, et al.
The New England Journal of Medicine|October 4, 2008
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, et al.
Pageof 45